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 Nipradilol (Nip), which has α1- and β-adrenoceptor antagonist and nitric oxide 
(NO)-donating properties, has clinically been used as an anti-glaucomatous agent in 
Japan. NO mediates cellular signaling pathways that regulate physiological functions. 
The major signaling mechanisms mediated by NO are cGMP-dependent signaling and 
protein S-nitrosylation-dependent signalings. Nip has been described as having 
neuroprotective effects through cGMP-dependent pathway in retinal ganglion cells 
(RGCs). However, the effect seems to be partial. On the other hand, whether Nip can 
prevent cell death through S-nitrosylation is not yet clarified. In this study, we therefore 
focused on the neuroprotective mechanism of Nip through S-nitrosylation. Nip showed 
a dramatic neuroprotective effect against oxidative stress-induced death of RGC-5 cells. 
However, denitro-nipradilol, which does not have NO-donating properties, was not 
protective against oxidative stress. Furthermore, an NO scavenger significantly reversed 
the protective action of Nip against oxidative stress. In addition, we demonstrated that 
α1- or β-adrenoceptor antagonists (prazosin or timolol) did not show any 
neuroprotective effect against oxidative stress in RGC-5 cells. We also demonstrated 
that Nip induced the expression of the NO-dependent antioxidant enzyme, heme 
oxygenase-1 (HO-1). S-nitrosylation of Kelch-like ECH-associated protein by Nip was 
shown to contribute to the translocation of NF-E2-related factor 2 to the nucleus, and 
triggered transcriptional activation of HO-1. Furthermore, RGC death and levels of 
4-hydroxy-2-nonenal (4HNE) were increased after optic nerve injury in vivo. 
Pretreatment with Nip significantly suppressed RGC death and accumulation of 4HNE 
after injury through a HO-1 activity-dependent mechanism. These data demonstrate a 









Nip) has vasodilator activity owing to nitric oxide (NO) released from the nitroxy 
moiety (Adachi et al., 1995). Nip lowers intraocular pressure via its selective 
α1-adrenoceptor (Kou et al., 1984; Ohira et al., 1985) and non-selective β-adrenoceptor 
(Uchida et al., 1983; Kawashima et al., 1984) antagonist properties. Nipradilol is 
registered as an anti-glaucoma agent in Japan. More recently, a protective effect of Nip 
has been demonstrated in various neuronal cells (Tomita et al., 2002, Taguchi et al., 
2006) including retinal ganglion cells (RGCs; Nakazawa et al., 2002). It has been 
reported that Nip has a neuroprotective effect on N-methyl-D-aspartate 
(NMDA)-induced damage to RGCs (Mizuno et al., 2001). The authors concluded that 
the protective effects of Nip were due to NO-dependent actions because both selective 
α1- and non-selective β-adrenoceptor antagonists had no protective effects. However, 
the mechanism of NO-mediated protection against cell damage is not clear. NO is a 
gaseous messenger molecule biosynthesized from L-arginine and molecular oxygen by 
NO synthase. Many reports suggest that excess production of NO plays a crucial role in 
neuronal cell death (Dawson et al., 1991; Nowicki et al., 1991, Smith et al., 1997), 
including in death of RGCs (Park et al., 2007). In contrast, several lines of evidence 
indicate that NO can prevent neuronal death (Chiueh et al., 1999; Lipton, 1999), 
including death of RGCs (Imai et al., 1997; Mastrodimou et al., 2008), through an 
NO/cGMP-dependent pathway (Andoh et al., 2002). Tomita and colleagues (2002) 
reported that the neuroprotective effect of Nip can be partially reversed by inhibiting 
protein kinase G. We wanted to test whether the neuroprotective action of Nip might 
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also be mediated by antioxidant effects via the S-nitrosylation pathway, as Naito and 
collaborators (1994) reported that Nip inhibits H2O2-induced lipid peroxidation. 
Antioxidative proteins, including heme oxygenase-1 (HO-1: EC 1.14.99.3), are induced 
by activation of Kelch-like ECH-associated protein (Keap1) / NF-E2-related factor 2 
(Nrf2) signaling (Kaspar et al., 2009; Kurauchi et al., 2009). Thus, in this study, we 
specifically investigated the possibility that the neuroprotective mechanism of Nip 
against oxidative stress and optic nerve injury is mediated through the Keap1/Nrf2 
pathway in cultured RGC-5 cells and mouse RGCs, respectively.  
 
2. Material and methods 
2.1. Chemicals 
Nip and denitro-nipradilol (DeNip) were a kind gift from Kowa (Japan). Timolol 
maleate, prazosin hydrochloride, and dithiothreitol (DTT) were purchased from Wako 
(Osaka, Japan). 2-(4-Carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide, 
sodium salt (c-PTIO) and 4', 6-diamino-2-phenylindole (DAPI) were obtained from 
Dojindo (Kumamoto, Japan). An HO-1 inhibitor, Sn-mesoporphyrin (SnMP), was 
obtained from Frontier Scientific Inc. (Logan, UT). t-Butyl hydroperoxide (tBOOH) 
was obtained from Sigma-Aldrich (Tokyo, Japan).  
 
2.2. Cell culture 
The cell line RGC-5, a transformed cell line with some ganglion cell characteristics, 
was originally produced by Dr. N. Agarwal of the University of North Texas Health 
Science Center and was received from a line maintained by Dr. H. Hara at Gifu 
Pharmaceutical University (Krishnamoorthy et al., 2001). RGC-5 cells were cultured in 
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low-glucose Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal 
bovine serum (FBS), 100 U/ml of penicillin and 100 μg/ml of streptomycin in a 
humidified atmosphere of 95% air and 5% CO2 at 37°C. The cells were passaged by 
trypsinization every 3-4 days. RGC-5 cells (5×103 cells/ml) were cultured overnight 
before use. After washing with DMEM, the cells were cultured in medium containing 
1% FBS to prevent cell overgrowth.  
 
2.3. Measurement of NO production 
The NO indicator, 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate (DAF-FM 
DA; Daiichi Pure Chemicals, Tokyo, Japan), reacts with NO to form a fluorescent 
triazole compound. RGC-5 cells were cultured and washed twice with Earle's balanced 
salt solution (EBSS), treated with Nip or DeNip at 37°C for 1 h, and then 10 μM 
DAF-FM DA was added to the culture dishes for 30 min to 1 h. The samples were then 
washed with EBSS and centrifuged at 100 g for 5 min at 23°C. The supernatants were 
discarded and the pellets resuspended in 500 μl of EBSS. The fluorescence intensity of 
each cell suspension was measured at an excitation/emission wavelength of 495 nm/515 
nm using a Fluoroskan Ascent Fluorescence Reader (Thermo Electron Corporation, 
Woburn, MA) 
 
2.4. MTT assay 
Cell death was estimated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. An aliquot (20 μl) of 2.75 mg/ml MTT in phosphate-buffered 
saline (PBS) was added to 200 μl of culture medium as described previously (Koriyama 
et al. 2003). The reaction mixture was incubated at 37°C for 3 h, prior to adding 200 μl 
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HCl/isopropanol to solubilize the resultant purple formazan product. Absorbance was 
measured at 550 nm using a Bio-Rad Model 680 Absorbance Microplate Reader 
(Hercules, CA). Experiments were repeated at least three times and compared with the 
control experiment.  
 
2.5. RNA isolation and RT-PCR 
Total RNA was isolated from RGC-5 cells using Sepasol RNA I (Nacalai Tesque, Japan). 
Four types of cDNA fragments were obtained by RT-PCR, using an RNA PCR kit 
(AMV) Ver.3 (TaKaRa, Japan) with the following specific primers: HO-1: 5′- 
AGCATGCCCCAGGATTTGTC -3′(forward) and 5′- 
ACCAGCAGCTCAGGGTGAGT -3′ (reverse), NAD(P)H: quinine oxidoreductase-1 
(NQO-1): 5′- GGCGAGAAGAGCCCTGATTG -3′ (forward), 5′- 
GTGGTGATAGAAAGCAAGGT -3′ (reverse), and glutamate cysteine ligase catalytic 
subunit (GCLC): 5′- TCAAAGGCTTCTCAGCCAGA -3′ (forward), 5′- 
AGATCTCCTTATCGATGGTC-3′ (reverse). PCR products were electrophoresed and 
stained with ethidium bromide. The product bands were quantified using Scion Image 
software (Scion Corporation, USA), and normalized to the corrected level of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA.  
 
2.6. S-Nitrosylation analyses  
S-Nitrosylation was assessed by a modified biotin switch assay (Jaffrey et al., 2001) 
using the S-nitrosylated Protein Detection Assay Kit (Cayman Chemical Ann Arbor, 
Michigan, USA). RGC-5 cells exposed to 20 μM Nip for 1 h were harvested and lysed 
at 4°C. Free thiols were blocked by adding S-methyl methanethiosulfonate. 
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Biotinylation of nitrosothiols was carried out with maleimide-biotin. Biotinylated 
proteins were further purified by overnight incubation with NeutrAvidin-coupled 
agarose beads (Pierce-Thermo Scientific). After washing the beads three times with 
PBS, proteins were recovered by addition of Laemmli sample buffer, and heated at 85°C 
for 10 min. The amount of S-nitrosylated protein in the samples was determined by 
western blot analysis using anti-Keap1 (Santa Cruz Biotechnology, CA, USA, 1:500) 
and anti-caspase-3 (Calbiochem, La Jolla, CA, USA, 1:500) primary antibodies. 
 
2.7. Subcellular fractions of Nrf2 protein   
Cells were lysed with hypotonic buffer (10 mM HEPES-KOH (pH7.9), 10 mM KCl, 1.5 
mM MgCl2, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, protease inhibitor 
cocktail (Sigma-Aldrich, Tokyo, Japan)) and centrifuged at 10,000 g for 15 min at 4°C. 
The supernatants comprised the cytoplasmic fraction. The pellets were incubated with a 
nuclear lysis buffer containing 20 mM HEPES-KOH (pH7.9), 400 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1 mM DTT, 5% glycerol, and protease inhibitor cocktail for 30 
min on ice. The lysates were centrifuged at 18,000 g for 15 min at 4°C. The 
supernatants comprised the nuclear fraction.  
 
2.8. Western blot analysis 
RGC-5 cells cultured under various conditions were isolated and aliquots containing 30 
μg of protein were subjected to polyacrylamide gel electrophoresis using a 12.5% gel as 
described previously (Koriyama et al. 2009a). The separated proteins were transferred 
to a nitrocellulose membrane and incubated sequentially with primary and secondary 
antibodies. The signal for the Nrf2 protein bands (Cell Signaling Technology, Beverly, 
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MA) was detected using a BCIP/NBT Kit (KPL, Gaithersburg, MD). An antibody 
against β-actin (GeneTex, San Antonio, TX, 1:500) was used as an internal standard. 
The protein bands isolated in samples from cells under various culture conditions were 
analyzed densitometrically using Scion Image Software (Scion Corp.). All experiments 
were repeated at least three times. 
 
2.9. Chromatin immunoprecipitation assay  
Chromatin immunoprecipitation (ChIP) assays were performed using a ChIP Assay Kit 
(Upstate/Millipore Corporation, Temecula, CA, USA). Briefly, proteins and DNA were 
cross-linked with formaldehyde, and cells were lysed in SDS-lysis buffer and then 
sonicated. To reduce non-specific background, the sheared chromatin was incubated 
with Protein A agarose/Salmon Sperm DNA. The remaining chromatin was 
immunoprecipitated with IgG (as control) or Nrf2 antibodies. DNA-protein complexes 
were eluted from the antibody with elution buffer containing 1% SDS and 0.1 M 
NaHCO3, as well as formaldehyde reversed cross-links by 5 M of NaCl and heating at 
65°C for 4 h. DNA was purified and PCR was performed using primers that spanned the 
HO-1 E1 enhancer (Alam and Cook, 2003). The primers used were: E1, 5′- 
GATTTCCTCACTGCCCTGAA -3′ (forward) and 5′- CTTCTGCCCGAGGTTAAAGC 
-3′ (reverse). A 1.5% agarose gel with ethidium bromide was used to separate and 
examine the PCR products. 
 
2.10. Animals and surgery 
All experiments on animals were performed in accordance with the guidelines for 
animal experiments of Kanazawa University. Mice (8-9 weeks old Male, C57BL/6) 
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were anesthetized by intraperitoneal injection of sodium pentobarbital (30-40 mg/kg 
body weight). Intravitreal injection of Nip and/or SnMP was performed with a Hamilton 
microsyringe with 30G needle. The volume of injection was set at 5 μl of total volume 
after removal of the same volume of vitreous fluid. The optic nerve was crushed 1 mm 
away from the eyeball with forceps as described previously (Koriyama et al., 2008). 
Mice were reared in clear plastic cages and kept under 12 h light–dark cycle at 23°C. 
 
2.11. Immunohistochemistry 
Tissue fixation and cryosectioning were performed as described previously (Koriyama 
et al., 2009b). Briefly, the eyes were enucleated and fixed in 4% paraformaldehyde in 
0.1 M phosphate buffer (pH 7.4), and cryoprotected in 5% sucrose for 2 h at 4°C. The 
sucrose concentration was gradually increased from 5 to 20%. The eyes were then 
embedded in optimal cutting temperature compound (Tissue Tek; Miles, Eikhart, IN) 
and cryosectioned at a thickness of 12 µm. Frozen sections were mounted onto 
silane-coated glass slides and air-dried. We sampled retinal sections within 300 μm from 
the optic disc. After washing and blocking with Blocking One (Nakalai Tesque, Kyoto), 
retinal sections were incubated with the primary anti-HO-1 antibody (Santa Cruz 
Biotechnology, 1:300) and anti-βIII-tubulin (TUJ1, Abcam, 1:500) at 4°C overnight. 
The sections were then incubated with Alexa Fluor anti-IgG (Molecular Probes, 
1:2,000) at 23°C. As a quantification of HO-1 immunoreactivity, higher-resolution 
images of two areas at 1500 µm distance from optic disc were obtained (40 
magnifications, 5 mice in a group) as representative data. Assessment of fluorescence 
intensity of ganglion cell layer was performed using ImageJ software (Wayne Rasband, 
NIH, Bethesda, MD). In the Nrf2 translocation study, RGC-5 cells were fixed in 0.1% 
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glutaraldehyde (Wako, Osaka, Japan) for 30 min at 23°C. Nrf2 translocation from 
cytosol to the nucleus was confirmed by double staining for Nrf2 and DAPI. 
 
2.12. Dot blotting analysis for 4-hydroxy-2-nonenal  
To assess the antioxidant effect of Nip, we performed dot blotting analysis for 
4-hydroxy-2-nonenal (4HNE), a marker of lipid peroxidation. After 1 day of 
pretreatment with Nip, in the presence or absence of SnMP, and 4 days of treatment 
with optic nerve injury, retinal samples were isolated and homogenized. Equal amounts 
of protein (30 μg) were applied to a Hybri-SLOT apparatus (Gibco BRL) and 
transferred to a nitrocellulose membrane (Whatman) by vacuum filtration. After 
blocking with 3% bovine serum albumin for 1 h at 23°C, the samples were incubated 
with an anti-4HNE antibody (1:100; NOF Corporation) at 4°C overnight, followed by 
incubation with anti-mouse IgG antibody (Santa Cruz Biotechnology, CA, USA) for 1 h 
at 23°C. Antibody-bound protein bands were detected using a BCIP/NBT Kit and 
analyzed densitometrically as described above. All experiments were repeated at least 
three times. 
 
2.13. Counting of surviving RGCs 
RGC survival was evaluated in flat-mounted retinas by immunohistochemistry using a 
mouse antibody against βIII-tubulin (TUJ1, Abcam, 1:500), followed by a fluorescent 
secondary antibody. Images of 8 prespecified areas of 2 mm away from the optic disc 
(middle region of the retina) were captured by fluorescent microscopy (under x200 
magnification; E600, Nikon) and positive cells were counted using ImageJ software. 
Cell densities were calculated as mean values of surviving RGCs per 0.14 mm2 in 8 
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specified areas. Data are presented as means ± S.E.M on five mice per group.  
 
2.14. Terminal transferase-mediated dUTP nick-end labeling (TUNEL) staining  
After fixation and cryosection, retinal sections were incubated in 0.1% Triton X-100, as 
well as 0.1 % sodium citrate for 15 min. Then, sections were further incubated with 20 
μg/ml proteinase K in 10 mM Tris/HCl (pH 7.4) at 37°C for 20 min and rinsed in PBS. 
DNA fragmentation of cells undergoing apoptosis was detected using an in situ cell 
death detection kit (Roche, Mannheim, Germany), containing terminal transferase and 
fluorescence dUTP. The retinal sections were incubated in this reaction mixture 
overnight at 37°C, and rinsed twice in PBS. The number of TUNEL positive cells was 
counted by fluorescent microscopy (x200 magnification; E600, Nikon) in visual field of 
middle region of retina (including middle point between optic disc and the edge of 
retina). Data are presented as means ± S.E.M on five mice per group (n=25). 
 
2.15. Statistics 
All results are reported as means ± S.E.M for three to five experiments. Differences 
between groups were analyzed using ANOVA followed by Dunnett’s multi-comparison 




3.1. Nitric oxide generation by Nip in RGC-5 cells 
We first tested whether Nip could induce the generation of NO in RGC-5 cells. Nip (20 
µM) significantly increased the fluorescence intensity of the NO indicator, DAF-FM 
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DA, in RGC-5 cells at 0.5-1 h after treatment (Figs. 1C and D). DeNip has weak 
selective α1-adrenoceptor and non-selective β-adrenoceptor antagonist properties but no 
NO-donating action (Uchida et al., 1983). Compared with no treatment (Fig. 1A), the 
same concentration of DeNip did not increase the fluorescence intensity in RGC-5 cells 
(Fig. 1B)  
 
3.2. Protective effects of Nip against oxidative stress in RGC-5 cells. 
To evaluate the neuroprotective effect of Nip against oxidative stress in RGC-5 cells, we 
constructed oxidative stress model in culture with hydrogen peroxide (H2O2), tBOOH, 
and serum withdrawal. Treatment with 300 µM H2O2 for 24 h induced cell death to 60% 
of no treated control RGC-5 cells (Fig. 2A). Pretreatment with Nip 4-6 h prior to H2O2 
exposure produced a maximum protective effect. No protective effect was observed 
when Nip was applied to RGC-5 cells 0-2 h before H2O2 exposure. Additionally, Nip 
was protective when added to RGC-5 cells following H2O2 treatment (Fig. 2B), and this 
protective effect of Nip was reversed by the NO scavenger, c-PTIO (Fig. 2B). Nip also 
protected RGC-5 cells from oxidative stress induced by either tBOOH (Fig. 2C) or 
serum withdrawal (Fig. 2D). Furthermore, c-PTIO significantly suppressed the 
neuroprotective effect of Nip against both tBOOH (Fig. 2C) and serum withdrawal (Fig. 
2D). In contrast, DeNip did not show any neuroprotective effect against serum 
withdrawal-induced cell death (Fig. 2E).  
 
3.3. HO-1 induction by Nip in RGC-5 cells 
Next, we tested whether Nip can induce the expression of the antioxidative enzyme, 
HO-1, in RGC-5 cells. After 4 h of treatment with 20 µM Nip, we found that HO-1 
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mRNA was significantly increased in RGC-5 cells (Fig 3A). Indeed, levels of HO-1 
mRNA in RGC-5 cells were shown to be greatest after 4 h treatment with Nip (1.5-fold 
compared with 0 h; Fig. 3B). Other antioxidative enzymes, such as NQO-1 and GCLC, 
were not increased for up to 12 h after treatment with Nip (data not shown). HO-1 
protein was also increased by 1.7-fold after 4-8 h treatment with Nip, and then declined 
by 12 h after treatment (Fig. 3C). This peak in HO-1 expression at 4-8 h following 
treatment with Nip is consistent with the maximum protective effect of Nip when 
applied 4-6 h before H2O2 exposure (Fig. 2A). In the presence of the HO-1 specific 
inhibitor, SnMP (10 µM), the neuroprotective effect of Nip against H2O2 decreased from 
80% to 60% (Fig.3D). SnMP alone did not affect the viability of RGC-5 cells, either in 
the presence or absence of H2O2. The neuroprotective effect of Nip against serum 
deprivation was also reduced by SnMP in RGC-5 cells (data not shown). 
 
3.4. α1- and β-adrenoceptor antagonists are not protective against oxidative stress in 
RGC-5 cells. 
We examined the possible involvement of α1-adenoceptors and β-adrenoceptors in the 
Nip-induced neuroprotection of RGC-5 cells using the specific antagonists, prazosin 
and timolol, respectively. Results from RT-PCR confirmed that RGC-5 cells express 
both α1- and β-adrenoceptors (data not shown). Neither prazosin (Fig. 4A) nor timolol 
(Fig. 4B) prevented H2O2-induced death of RGC-5 cells. Furthermore, prazosin and 
timolol did not show any protective effect against serum withdrawal-induced cell death 
(data not shown). DeNip, prazosin or timolol did not alter HO-1 mRNA expression for 
12 h (Fig. 4C). These results suggest that the neuroprotective effect of Nip is not 




3.5. Nip induces NO/S-nitrosylation dependent translocation of Nrf2 to the nucleus in 
RGC-5 cells. 
To test the involvement of the Keap1/Nrf2 system in the Nip-induced increase in HO-1, 
we analyzed the levels of Nrf2 in the nucleus of RGC-5 cells under three conditions: (i) 
no treatment (Figs. 5A-C), (ii) treatment with 20 µM Nip (Figs. 5D-F), and (iii) 
treatment with 20 µM Nip plus 100 µM c-PTIO (Figs. 5G-I). Following treatment, cells 
were stained for Nrf2 (Figs. 5A, D and G) and with DAPI (Fig. 5B, E and H), and 
images of this staining were merged (Fig. 5C, F and I) to visualize Nrf2 in nuclei. In 
non-treated RGC-5 cells, Nrf2 in the cytoplasm was diffusely stained in the cytoplasm 
(Fig. 5A). Nip induced translocation of Nrf2 into the nucleus (Fig. 5D). This 
Nip-induced increase of Nrf2 staining in nuclei was dramatically blocked by c-PTIO 
treatment (Fig. 5G). Nuclear fraction analysis quantitatively confirmed this 
translocation of Nrf2 from the cytoplasm to the nucleus. The nuclear level of Nrf2 
protein was increased at 2 h following Nip treatment. DTT, an S-nitrosylation blocker, 
significantly inhibited nuclear translocation of Nrf2 (Fig. 5J). DTT and c-PTIO alone 
did not affect Nrf2 translocation as compared with no treatment. The proportion of Nrf2 
that translocated to the nuclei was calculated and graphed in Fig. 5K. These results 
suggest that Nip-mediated translocation of Nrf2 to the nucleus is dependent on 
NO/S-nitrosylation pathways. 
 
3.6. Nip stimulated Keap1 S-nitrosylation and Nrf2 binding to the E1 enhancer in 
RGC-5 cells 
To further confirm the association between HO-1 expression and the NO/S-nitrosylation 
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pathway, we investigated the effects of an NO scavenger and S-nitrosylation blocker on 
HO-1 induction by Nip. Nip (20 µM) increased HO-1 mRNA 1.6-fold within 4 h 
following treatment (Fig. 6A and B). This increase of HO-1 mRNA was blocked by 
c-PTIO (Fig. 6A) and DTT (Fig. 6B). Next, we investigated whether Nip modified the 
oxidative state of the intracellular sensor molecule, Keap1. After removal of free thiols, 
S-nitrosylation of Keap1 was detected by biotinylating nitrosothiols and isolated with 
avidin-coupled beads, and was then measured by western blotting with an anti-Keap1 
antibody. Nip treatment increased S-nitrosylated Keap1 1.8-fold compared with no 
treatment (Fig. 6C). The increase of S-nitrosylation of Keap1 by Nip was significantly 
suppressed by pretreatment with either c-PTIO or DTT. This effect was specific to 
Keap1 but not to caspase-3(Fig. 6D). To further assess the involvement of Nrf2 on 
HO-1 gene expression, we determined binding of Nrf2 to the HO-1 enhancer E1 
element of genomic HO-1 DNA. ChIP assays with an antibody directed against Nrf2 
showed high binding of Nrf2 to the E1 enhancer motif. Nip treatment for 2 h 
significantly enhanced Nrf2 binding to the E1 enhancer by about 3-fold (Fig. 6E). 
Pretreatment with c-PTIO for 1 h completely reversed the binding of Nrf2 to the E1 
enhancer. The ChIP assay performed with IgG did not show increased binding of Nrf2 
to the E1 enhancer, compared with no treatment (Fig. 6E). 
 
3.7. Nip prevents 4HNE accumulation in mouse RGCs after optic nerve injury. 
To further validate the protective effect of Nip in mouse RGCs in vivo after optic nerve 
injury, we investigated the effect of intraocular injection of Nip on HO-1 expression. 
Figures 7 (A) to (I) show HO-1 immunohistochemistry in the mouse retina. Panels 
(A-C) show the untreated retina. Panels (D-F) show retina treated with Nip at 1 day. 
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Strong HO-1 immunoreactivity was observed in the mouse RGC layer after treatment 
with 0.3 nmol Nip (Fig. 7D), compared with no treatment (Fig. 7A). The Nip-induced 
increase of HO-1 expression in the ganglion cell layer was shown to localize in RGCs 
by staining with TUJ-1 (Fig.7E). The colocalization of HO-1 and TUJ-1 in the RGCs 
can be seen in the merged images (Fig. 7F). Levels of HO-1 protein decreased to control 
levels within 3 days after Nip treatment (Fig. 7G-I). Quantification of HO-1 expression 
is shown in Fig. 7J. We also measured the accumulation of 4HNE, a final product of 
lipid peroxidation (Koriyama et al., 2009b), following optic nerve injury in the mouse. 
Optic nerve injury increased 4HNE accumulation in the mouse retina by 2.5-fold at 7 
days post-injury, compared with the intact retina (Fig. 7K). Nip significantly decreased 
the levels of 4HNE. The Nip-mediated decrease in 4HNE accumulation after nerve 
injury was significantly suppressed by co-injection of 0.15 nmol SnMP (Fig. 7K). 
Intraocular treatment with Nip or SnMP alone did not alter 4HNE levels compared with 
no treatment. 
 
3.8. Nip prevents RGC death after optic nerve injury. 
Staining with TUJ1 revealed that optic nerve injury induced apoptotic cell death of 
RGCs 10 days after injury (Figs. 8B and E, and Table 1) compared with the intact retina 
(Fig. 8A). The death of RGCs after injury was clearly blocked by pretreatment with 0.3 
nmol Nip (Figs. 8C and E). This neuroprotective effect of Nip in mouse RGCs 
following nerve injury was not seen with treatment with 0.3 nmol Nip plus 0.15 nmol 
SnMP (Figs. 8D and E). SnMP alone did not affect RGC death compared with no 
treatment. Figures 9(A) to (D) show TUNEL staining in the mouse retina. Optic nerve 
crush induced apoptotic cell death of RGCs with TUNEL staining 10 days after injury 
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(Fig. 9B) compared with the intact retina (Fig. 9A). The cell death of RGCs after injury 
was clearly blocked by pre-treatment with Nip (Fig. 9C). This neuroprotective effect of 
Nip in RGCs following nerve crush could not be seen by Nip plus SnMP (Fig. 9D). 
SnMP alone did not affect RGC cell death (data not shown). Figure 9(E) illustrates the 
quantitative data of RGCs cell death after ONI. 
 
4. Discussion 
4.1. The antioxidative effect of Nip is mediated through NO generation and increased 
HO-1 expression.  
In the present study, we demonstrated that the potent NO donor, Nip, is neuroprotective 
against oxidative stress models in the RGC-5 cell line and mouse RGCs in vivo. Since 
DeNip, which does not release NO, did not induce HO-1 expression or protect RGC-5 
cells against oxidative stress, we suggest that the neuroprotective effect of Nip is 
mediated through the generation of NO.  
Nip provides neuroprotection against axotomy of rat RGCs (Mizuno et al., 2001; 
Nakazawa et al., 2002) and prevents apoptosis mediated by NMDA receptor 
excitotoxicity in the retina, mainly through the production of NO gas (Kitaoka et al., 
2002). The neuroprotective role of Nip may also be mediated through antiapoptotic 
pathways, specifically through down-regulation of Bax and caspase-9 (Ando et al., 
2005). Because Nip has selective α1- and non-selective β-adrenoceptor antagonist 
properties, we used prazosin as an α1-blocker and timolol as a β-blocker. However, 
neither prazosin nor timolol induced HO-1 or influenced the survival rate in our 
oxidative stress models, despite RGC-5 cells having both α1- and β-adrenoceptors (data 
not shown). Nip has previously been shown to have a neuroprotective effect against 
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NMDA treatment of RGCs (Mizuno et al., 2001) and axotomy (Nakazawa et al., 2002), 
which was not reversed by prazosin or timolol. Moreover, DeNip did not induce 
expression of antioxidative enzymes or show any neuroprotective effect against 
oxidative stress in the present study. These results indicate that the protective effect of 
Nip works in a NO-dependent fashion. 
 
4.2. Nip induces Keap1 S-nitrosylation and HO-1 protein expression through Nrf2 
translocation to the nucleus in RGC-5 cells. 
In general, NO mediates neuroprotection through two main signaling pathways: the 
NO/cGMP pathway (Andoh et al., 2002) and the S-nitrosylation pathway (Sun et al., 
2006). Although the neuroprotective effect of Nip was previously reported to be 
mediated through a cGMP-dependent protein kinase pathway (Tomita et al., 2002), the 
effect seems to be partial. In addition, Naito and colleagues (1994) reported that Nip 
inhibited hydrogen peroxide-induced lipid peroxidation. Because of these previous 
findings, we focused on the S-nitrosylation-dependent antioxidative mechanism of Nip. 
NO-donating aspirin induces antioxidative enzymes and shows antioxidant effects in 
cancer cells (Gao et al., 2006). Buckley and others (2003, 2008) reported that NO 
stimulates Nrf2 nuclear translocation in vascular endothelium. NO also activates 
Keap1/Nrf2 by S-nitrosylation in carcinoma cells (Li et al., 2009). However, whether 
Nip induces S-nitrosylation of Keap1 and antioxidative enzymes is unclear. Thus, we 
investigated the signaling pathway leading to induction of antioxidative enzymes by Nip. 
We showed that Nip induced HO-1. HO-1 (Maines 1988; Poss and Tonegawa 1997) is 
an enzyme that degrades intracellular heme to free iron, carbon monoxide, and 
biliverdin. Carbon monoxide plays a significant role in anti-apoptosis and 
21 
 
anti-inflammation (Otterbein et al., 2000, 2003). Furthermore, bilirubin, converted from 
biliverdin (Nishimura et al., 1996), acts as a strong reactive oxygen species scavenger 
and attenuates lipid peroxidation related to 4HNE (Deguchi et al., 2008). Biliverdin also 
exerts anti-inflammatory and neuroprotective effects (Hung et al., 2010). In this study, 
SnMP partially reversed the Nip-mediated protection against oxidative stress. 
Furthermore, an in vivo study showed that Nip can dramatically suppress injury-induced 
4HNE accumulation and that SnMP can significantly reverse this effect. HO-1 is 
primarily involved in this survival effect against oxidative stress. Taken together, these 
data strongly suggest that the neuroprotective action of Nip against oxidative stress is 
caused by NO generation following antioxidant HO-1 induction in RGC-5 cells.  
Next, we studied the possibility that the induction of HO-1 by Nip is mediated through 
the Keap1/Nrf2 pathway. It is known that Nrf2 is a key transcription factor for the 
induction of antioxidative enzymes (Kaspar et al., 2009). Nip rapidly induced 
translocation of Nrf2 to the nucleus within 2 h of treatment. Translocation of Nrf2 was 
dependent on NO/S-nitrosylation, because c-PTIO and DTT significantly blocked the 
translocation of Nrf2, as well as the Nip-mediated neuroprotection and increase in HO-1 
expression. The induction of HO-1 is known to be dependent on the presence of 
antioxidant response element sites containing an E1 enhancer region in the HO-1 
promoter (Alam and Cook, 2003). Using the ChIP method, we confirmed increased 
levels of Nrf2 bound to the E1 enhancer of the HO-1 promoter in RGC-5 cells treated 
with Nip. The translocation of Nrf2 from the cytoplasm to the nucleus is regulated by 
the intracellular sensor protein, Keap1 (Li et al., 2009, Buckley et al., 2008). In this 
study, we demonstrated that Nip certainly increased S-nitrosylation of Keap1 by 
1.7-fold compared with no treatment. Tomita and collaborators (2002) discussed the 
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possibility that the neuroprotective action of Nip against serum deprivation in PC12 
cells might be caused by caspase-3 S-nitrosylation. However, this was not the case in 
RGC-5 cells. The results presented here demonstrate for the first time that the 
neuroprotective action of Nip is caused by induction of the HO-1 antioxidant protein in 
RGC-5 cells through activation of the Keap1/Nrf2 pathway by Keap1 S-nitrosylation. 
 
4.3. Neuroprotective action of Nip in mouse RGCs after nerve injury in vivo 
In our previous paper (Homma et al., 2007), we reported that more than half of adult rat 
RGCs became apoptotic 7 days after nerve injury. The death of RGCs following nerve 
crush was partly caused by hydroxyl radicals or super oxide anions (Levkovitch-verbin 
et al., 2000). Therefore, cell death was blocked by antioxidants such as N-acetylcysteine 
(Castagne and Clarke 1996). In this study, optic nerve injury increased 4HNE 
accumulation in the retina. Therefore, we studied mouse RGCs after nerve injury as an 
in vivo model of oxidative stress. Intraocular injection of Nip specifically induced HO-1 
expression in the RGCs 1 day post-injection. These results suggest that Nip induced 
HO-1 expression via NO generation. Further studies are needed to evaluate the 
molecular signaling involved in this Nip-mediated HO-1 induction in the retina in vivo. 
RGC death after nerve injury was significantly reduced by Nip. This protection 
depended on HO-1 induction, because the protective action of Nip was attenuated by 
co-injection with a HO-1 inhibitor. The Nip-induced decrease in 4HNE accumulation 
was also significantly suppressed by the HO-1 inhibitor. These results demonstrate for 
the first time that Nip protects mouse RGC death against oxidative stress in vitro and in 
vivo through the induction of the antioxidant HO-1 via the Keap1/Nrf2 pathway. This 
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Fig 1. Nitric oxide (NO) production by Nip in RGC-5 cells. 
NO production by Nip was evaluated in RGC-5 cells by DAF-FM DA staining (A-C). 
(A) Non-treated cells. (B) Cells treated with 20 μM DeNip for 1h. (C) Cells treated with 
20 μM Nip for 1h. Scale bar = 10 μm. (D) Quantitative data of fluorescence intensity 
were measured by a fluorescence plate reader. *P < 0.01 vs 0 h (n=6). X: no treatment, 
closed circle: DeNip, open circle: Nip. 
 
Fig 2. Protective effect of Nip against oxidative stress-induced death of RGC-5 cells. 
(A) Pretreatment with Nip for various time periods prior to 300 μM H2O2 exposure. A 
4-6 h pretreatment with Nip (20 μM) was sufficient to prevent H2O2-induced cell death. 
*P < 0.01 vs no treatment (n=6). (B) NO-dependent neuroprotective effect of Nip 
against H2O2-induced neurotoxicity in RGC-5 cells. *P < 0.01 vs no treatment, +P < 
0.01 vs H2O2 alone. (C) NO-dependent neuroprotective effect of Nip against 
tBOOH-induced neurotoxicity in RGC-5 cells. *P < 0.01 vs no treatment, +P< 0.01 vs 
tBOOH treatment (n=6). (D) NO-dependent neuroprotective effect of Nip against serum 
deprivation-induced neurotoxicity in RGC-5 cells. *P < 0.01 vs no treatment, +P< 0.01 
vs serum deprivation (n=6). (E) DeNip did not show a neuroprotective effect against 
serum deprivation-induced neurotoxicity in RGC-5 cells. *P < 0.01 vs no treatment 
(n=6).  
 
Fig 3. Nip induces HO-1 and HO-1 activity is necessary for the protective effect of Nip 
against oxidative stress in RGC-5 cells. 
(A) Nip induced HO-1 mRNA expression in a dose-dependent manner after 4 h 
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treatment. *P < 0.01 vs 0 μM (n=3). (B) Upregulation of HO-1 mRNA in RGC-5 cells 
after Nip treatment. *P < 0.01 vs 0 h (n=3). (C) Upregulation of HO-1 protein in RGC-5 
cells after Nip treatment. *P < 0.01 vs 0 h (n=3). (D) A HO-1 inhibitor, 
Sn-mesoporphyrin (SnMP), canceled the neuroprotection afforded by Nip against H2O2. 
*P < 0.05, **P < 0.01 vs no treatment, +P < 0.01 vs H2O2 treatment, #P < 0.01 vs H2O2 
plus Nip treatment (n=6).  
 
Fig 4. α1- and β-adrenoceptor antagonists did not show a protective effect against 
oxidative stress-induced RGC-5 cell death. (A) The α1-adrenoceptor antagonist, 
prazosin, did not affect H2O2-induced RGC-5 cell death. *P < 0.01 vs no treatment 
(n=6). (B) The β-adrenoceptor antagonist, timolol, did not affect H2O2-induced RGC-5 
cell death. *P < 0.01 vs no treatment (n=6). (C) DeNip, prazosin, and timolol did not 
induce HO-1 mRNA expression.   
 
Fig 5. NO/S-nitrosylation dependent translocation of Nrf2 to the nucleus by Nip in 
RGC-5 cells. 
(A, D, G) Immunohistochemical staining for Nrf2. Treatment with c-PTIO at 1 h prior 
to addition of Nip. (A) No treatment. Scale bar = 10 μm. (D) Treatment with 20 μM Nip 
for 2 h. (G) Treatment with Nip plus c-PTIO. (B, E, H) DAPI staining. (C, F, I) Merged 
images. (J) Levels of Nrf2 protein in nuclear fractions treated with Nip. *P < 0.01 vs no 
treatment, +P < 0.01 vs Nip treatment (n=3). (K) The proportion of Nrf2 translocation 





Fig 6. Nip induces S-nitrosylation of Keap1 but not caspase-3 in RGC-5 cells. (A) 
c-PTIO canceled the Nip-mediated increase in HO-1 mRNA. *P < 0.01 vs no treatment 
(n=3). (B) DTT attenuated the HO-1 mRNA induction by Nip. *P < 0.01 vs no 
treatment (n=3). (C) S-nitrosylation of Keap1 by Nip. RGC-5 cells were exposed to 20 
μM Nip for 1 h before undergoing the biotin-switch assay of protein. *P < 0.01 vs no 
treatment, +P < 0.01 vs Nip treatment (n=3). (D) Nip did not induce S-nitrosylation of 
caspase-3 in RGC-5 cells (n=3). (E) ChIP assay demonstrates binding of Nrf2 to the 
HO-1 E1 enhancer following treatment with Nip for 2 h, with or without c-PTIO 
pretreatment for 1 h. The band shows PCR products of the E1 enhancer.  
 
Fig 7. HO-1 induction and prevention of nerve injury-induced 4HNE accumulation by 
Nip in mouse retina. (A-I) Nip induction of HO-1 in the mouse retina. (A, D, G) 
Immunohistochemistry for HO-1 at 0 days (A), 1 day (D) and 3 days (G). (B, E, H) 
TUJ-1-positive RGCs at 0 days (B), 1 day (E) and 3 days (H). (C, F, I) Merged images 
at 0 days (C), 1 day (F) and 3 days (I). Scale bar = 20 μm. INL; inner nuclear layer, 
GCL; ganglion cell layer. (J) The level of HO-1 protein expression was quantified by 
analysis of fluorescence intensity and represented on the graph. *P < 0.01 vs 0 days 
(n=10). (K) Nip-mediated prevention of nerve injury-induced 4HNE accumulation via 
HO-1 activation. 4HNE production was measured by dot blotting analyses with an 
anti-4HNE antibody. *P < 0.01 vs intact retina, +P < 0.01 vs injury, #P<0.01 injury plus 
Nip treatment (n=3). ONI; optic nerve injury. 
 
Fig 8. Nip-mediated RGC survival after optic nerve injury is dependent on HO-1. 
(A-D) Retinal whole mounts immunostained with TUJ-1 to visualize surviving RGCs 
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densities. (A) Intact retina. Scale bar= 20 μm. (B) Injury. (C) ONI plus Nip treatment. 
(D) ONI plus Nip plus SnMP treatment. (E) Quantification of surviving RGCs (Number 
of RGCs/ mm2). *P < 0.01 vs intact retina, +P < 0.01 vs injury, #P < 0.01 vs injury plus 
Nip treatment (n = 8). ONI; optic nerve injury. 
 
Fig. 9 Neuroprotective effect of Nip in the rat retina in vivo. (A–D) TUNEL staining in 
retina after optic nerve injury for 10 days. (A) Intact retina, (B) optic nerve injured 
retina, (C) ONI plus Nip, (D) ONI plus Nip with SnMP. Scale bar = 100 μm. INL; inner 
nuclear layer, GCL; ganglion cell layer, Arrows indicate TUNEL-positive cells. (E) 
Graphical representation of the number of TUNEL-positive cells in the GCL per visual 
fields (x200 magnification). * P < 0.01 vs intact retina, + P < 0.01 vs injury, # P< 0.01 
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